First published 9/28/2026, 9:21:15 AM · Last updated 9/28/2026, 9:21:15 AM

Tislelizumab combined with lenvatinib and liposomal irinotecan in a 78-year-old woman with advanced esophageal cancer after first-line immunochemotherapy failure: a case report with follow-up to September 4, 2026

Journal article reports a case of a 78-year-old woman with advanced esophageal cancer treated with tislelizumab, lenvatinib, and liposomal irinotecan after first-line immunochemotherapy failure, with follow-up to September 4, 2026. Publisher listed as AME Publishing Company and article published September 1, 2026.

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 5/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 2/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

Documents a single-patient clinical outcome for a combination therapy after first-line treatment failure.

Sources

Tislelizumab combined with lenvatinib and liposomal irinotecan in a 78-year-old woman with advanced esophageal cancer after first-line immunochemotherapy failure: a case report with follow-up to September 4, 2026

Report an issue